Drawing for VIVALEAS

USPTO serial 87376167

VIVALEAS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
GOODMAN, WENDY BETH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VIVALEAS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Todd M. Schneider

TODD M. SCHNEIDER PAUL HASTINGS LLP4747 EXECUTIVE DRIVE, 12TH FLOORC/O PAUL HASTINGS LLPSAN DIEGO, CA 92121

Goods and services

ClassDescriptionStatusFirst use
035Business consultation services; business consulting services relating to product manufacture, distribution, operations management services, logistics, and supply chain, and regulation compliance; business consulting and business management services in the fields of clinical medical services and patient relationship management for healthcare providers and payors; business administration of patient reimbursement programs; pharmaceutical cost management services and drug utilization review services; patient relationship management and patient relationship management consulting servicesACTIVE—
042Providing medical and scientific research information in the field of pharmaceuticalsACTIVE—
044Providing healthcare and medical information; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical and medical consultation; consulting in the field of nursing; health and medical counseling; providing wellness services, namely, personal assessments, personalized routines, maintenance schedules, and counseling; consulting services in the field of pharmaceuticalsACTIVE—
045Regulatory compliance consulting in the field of pharmaceuticals; providing patient advocate and case management services, namely, coordinating the procurement and administration of medicationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 18, 2018MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 18, 2018ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 14, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 19, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 19, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 30, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 16, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 16, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Aug 16, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 16, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 16, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 16, 2017ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Aug 1, 2017PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jul 13, 2017ALIEASSIGNED TO LIE—
Jun 13, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 12, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Jun 12, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 12, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 12, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 11, 2017DOCKASSIGNED TO EXAMINER—
Mar 24, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 23, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 21, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance